Phase 1 (Ph1) Clinical and Pharmacodynamic (PD) Study of a Pure MEK Inhibitor (MEKi), RO4987655, in RAS-BRAF Mutant Patient Populations with Advanced or Metastatic Solid Tumors Proffered Paper Session
Mechanisms of transformation by RAS oncogenes: searching for novel therapeutic approaches Treating Kras Mutated Tumours
